Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Spatial perturb-seq: single-cell functional genomics within intact tissue architecture.
PMID 41723140 · PMC13035813 · Nature communications · 2026 · 8 claims · 8 setups
Spatial Perturb-Seq simultaneously measures whole transcriptome (cell type), CRISPR barcodes (perturbation), spatial coordinates, and cell-cell interactions through a single Stereo-seq and/or Xenium run.
-
Full-text index only
nf-core/crisprseq: a versatile pipeline for comprehensive analysis of CRISPR gene editing and screening assays.
PMID 41551929 · PMC12805889 · NAR genomics and bioinformatics · 2026 · 8 claims · 5 setups
nf-core/crisprseq is the first generic pipeline enabling analysis of the broad spectrum of CRISPR designs, from targeted gene edits (KO, KI, BE, PE) to large-scale functional screens
-
Full-text index only
Massively parallel reporter assay for mapping gene-specific regulatory regions at single-nucleotide resolution.
PMID 41738738 · PMC12935429 · eLife · 2026 · 8 claims · 8 setups
LS-MPRA (BAC-based) and d-MPRA (systematic mutagenesis) are complementary methods for unbiased, high-resolution mapping of cis-regulatory modules.
-
Full-text index only
Integrative Multiomic Classification Reveals Distinct Origins and Evolutionary Trajectories of Thymic Epithelial Tumors.
PMID 41671387 · PMC13012242 · Cancer research · 2026 · 8 claims · 8 setups
TETs stratify into three molecular subgroups with distinct origins: GTF2I-type thymomas, CN-type thymomas, and thymic carcinomas
-
Full-text index only
A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules.
PMID 41534092 · PMC13044530 · Cancer research · 2026 · 8 claims · 8 setups
SWI/SNF-targeting PROTAC treatment reduces viability of CRPC-WNT (AR-negative) cell lines and organoids, not just AR-dependent CRPC